Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17250792 | 1.00 | OR51E2 (0.35) | OR51E2MEN1GAAKMT2ATGFBR1 | |
| SCHEMBL17245272 | 0.81 | SMN1; SMN2 (0.39) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL17245271 | 0.81 | SMN1; SMN2 (0.39) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL13484735 | 0.81 | SMN1; SMN2 (0.39) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL17245266 | 0.81 | PRKCA (0.31) | PRKCA | |
| SCHEMBL13484721 | 0.79 | SRR (0.34) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL12285641 | 0.79 | TDP1 (0.39) | MEN1GAAKMT2AMAPT | |
| SCHEMBL13484733 | 0.77 | LAP3 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11604860 | 0.77 | OR51E2 (0.32) | OR51E2MEN1GAAKMT2ATGFBR1 | |
| SCHEMBL27646096 | 0.77 | CHRM1 (0.44) | MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | MSR1, TPMT, M6PR | OR51E2 4422/4885MEN1 654/4885GAA 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.